Expert Series: The Road Ahead: Navigating the FDA Update on Elamipretide for Barth syndrome

Join MitoAction CEO, Kira Mann, Barth Syndrome Foundation CEO, Emily Milligan, and Stealth BioTherapeutics CEO, Reenie McCarthy for a discussion as we navigate the FDA’s most recent update on the application for elamipretide, a crucial treatment for the Barth syndrome community.